Visão geral da empresa
A clinical stage biopharmaceutical firm, DiaMedica Therapeutics Inc. is dedicated to enhancing the quality of life for individuals afflicted by severe ischemic diseases through the development of novel therapeutic candidates. The company operates within the healthcare sector, specifically focusing on the biotechnology industry, which implies a high-risk, high-reward environment characterized by significant research and development expenditures before commercialization. As of the latest data, the enterprise holds a market capitalization of $332.99M, employs a workforce of 35 individuals, and reports no annual revenue figures available for the trailing twelve months. The combination of a market cap exceeding three hundred million dollars with a complete absence of reported revenue indicates that the company is in a pre-commercialization phase where value is derived entirely from asset valuation and potential future cash flows rather than current operational profitability.
Saúde financeira
The company reports a net income of $-32,766,000 and an EBITDA of $-34,354,000 for the trailing twelve months, while revenue data is not available for the current period. The substantial gap between the reported net income and EBITDA, coupled with the negative figures, reveals a cost structure dominated by operating expenses and research costs that have not yet been offset by product sales or generated positive operating leverage. Free cash flow stands at $-18,192,124, indicating that the company is currently consuming cash reserves to fund its operations and development pipeline rather than generating surplus liquidity. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, which reflects the standard financial presentation for a pre-revenue biotechnology entity that has not yet achieved commercial sales volume to calculate meaningful profitability percentages. The balance sheet shows a cash position of $59.89M against total debt of $240,000, resulting in a debt-to-equity ratio of 0.43, which suggests the company maintains a conservative capital structure with minimal leverage relative to its equity base. Furthermore, the current ratio of 11.81 indicates an exceptionally strong short-term liquidity position, as the company holds assets far exceeding its current liabilities to comfortably meet obligations without refinancing risk. Return on equity is -67.7% and return on assets is -39.9%, metrics that reveal management is currently deploying capital to achieve future growth targets rather than generating immediate returns on the invested equity or asset base.
Avaliação de valorização
The trailing twelve-month P/E ratio is listed as N/A due to the lack of earnings, whereas the forward P/E stands at -7.39, implying that the market is pricing the stock based on anticipated future earnings rather than historical profitability. The price-to-book ratio is 5.92, indicating that the market values the company at nearly six times its book value, a premium often seen in biotech firms where investors assign high worth to intangible assets like intellectual property and pipeline potential. Since revenue is not available, the price-to-sales ratio is N/A, and the EV/EBITDA multiple is -7.96, suggesting that traditional valuation metrics based on sales or earnings are not applicable in the current stage of the company's lifecycle. The stock has traded between a 52-week low of $3.26 and a 52-week high of $10.42, meaning the current valuation sits within this historical volatility range defined by market sentiment regarding its clinical progress. With a beta of 1.15, the stock exhibits price volatility that is slightly higher than the broader market, reflecting the increased sensitivity of biotechnology equities to sector-specific developments and clinical trial outcomes.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, as the company has not yet generated commercial revenue to facilitate growth calculations or comparisons. Because the company does not pay a dividend, the dividend yield is N/A and the payout ratio is 0.0%, confirming that all available earnings and cash flow are retained and reinvested directly into the company's growth initiatives and clinical development programs rather than distributed to shareholders. The overall growth and income profile for DiaMedica Therapeutics Inc. is characterized by a complete reliance on capital appreciation derived from clinical trial success and future market penetration rather than current income generation or dividend distributions.